Windtree Therapeutics, Inc. (WINTW)
USD 0.0
(-61.11%)
USD 0.0
(-61.11%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -2.48 Million USD | 36.05% |
| 2022 | -3.89 Million USD | 79.99% |
| 2021 | -19.45 Million USD | -47.96% |
| 2020 | -13.14 Million USD | 19.16% |
| 2019 | -16.26 Million USD | -406.22% |
| 2018 | -3.21 Million USD | -124.37% |
| 2017 | 13.18 Million USD | -32.08% |
| 2016 | 19.41 Million USD | 241.47% |
| 2015 | -13.72 Million USD | 43.64% |
| 2014 | -24.34 Million USD | 64.08% |
| 2013 | -67.78 Million USD | -158.41% |
| 2012 | -26.23 Million USD | -184.88% |
| 2011 | -9.2 Million USD | -0.74% |
| 2010 | -9.14 Million USD | -114.81% |
| 2009 | -4.25 Million USD | 66.27% |
| 2008 | -12.61 Million USD | 41.81% |
| 2007 | -21.68 Million USD | -72.56% |
| 2006 | -12.56 Million USD | 70.17% |
| 2005 | -42.11 Million USD | -94.27% |
| 2004 | -21.68 Million USD | 23.46% |
| 2003 | -28.32 Million USD | -250.03% |
| 2002 | -8.09 Million USD | -119.86% |
| 2001 | -3.68 Million USD | 49.11% |
| 2000 | -7.23 Million USD | -106.72% |
| 1999 | -3.49 Million USD | -133.27% |
| 1998 | -1.5 Million USD | 76.19% |
| 1997 | -6.3 Million USD | -6200.0% |
| 1996 | -100 Thousand USD | -200.0% |
| 1995 | 100 Thousand USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | -1.06 Million USD | 57.29% |
| 2024 Q2 | 2.06 Million USD | 248.07% |
| 2023 FY | -2.48 Million USD | 36.05% |
| 2023 Q1 | -2.33 Million USD | 40.03% |
| 2023 Q4 | -2.48 Million USD | 52.21% |
| 2023 Q3 | -5.2 Million USD | 41.95% |
| 2023 Q2 | -8.97 Million USD | -284.36% |
| 2022 Q1 | -13.12 Million USD | 32.54% |
| 2022 Q3 | -5.65 Million USD | 30.14% |
| 2022 Q4 | -3.89 Million USD | 31.22% |
| 2022 FY | -3.89 Million USD | 79.99% |
| 2022 Q2 | -8.1 Million USD | 38.29% |
| 2021 Q2 | -26.13 Million USD | 21.4% |
| 2021 FY | -19.45 Million USD | -47.96% |
| 2021 Q4 | -19.45 Million USD | 8.8% |
| 2021 Q3 | -21.33 Million USD | 18.38% |
| 2021 Q1 | -33.25 Million USD | -152.88% |
| 2020 Q3 | -18.32 Million USD | 25.64% |
| 2020 Q4 | -13.14 Million USD | 28.25% |
| 2020 Q2 | -24.64 Million USD | -126.22% |
| 2020 FY | -13.14 Million USD | 19.16% |
| 2020 Q1 | -10.89 Million USD | 33.02% |
| 2019 FY | -16.26 Million USD | -406.22% |
| 2019 Q4 | -16.26 Million USD | -420.24% |
| 2019 Q1 | 7.39 Million USD | 330.22% |
| 2019 Q3 | 5.07 Million USD | 39.19% |
| 2019 Q2 | 3.64 Million USD | -50.67% |
| 2018 FY | -3.21 Million USD | -124.37% |
| 2018 Q3 | 4.6 Million USD | 147.53% |
| 2018 Q4 | -3.21 Million USD | -169.71% |
| 2018 Q1 | 646 Thousand USD | 135.59% |
| 2018 Q2 | 1.86 Million USD | 188.24% |
| 2017 Q2 | 22.47 Million USD | 32.36% |
| 2017 Q1 | 16.97 Million USD | -12.54% |
| 2017 FY | 13.18 Million USD | -32.08% |
| 2017 Q4 | -1.81 Million USD | -107.02% |
| 2017 Q3 | 25.84 Million USD | 15.02% |
| 2016 Q1 | -4.4 Million USD | 67.93% |
| 2016 FY | 19.41 Million USD | 241.47% |
| 2016 Q2 | 4.67 Million USD | 206.14% |
| 2016 Q4 | 19.41 Million USD | 53.86% |
| 2016 Q3 | 12.61 Million USD | 170.17% |
| 2015 Q1 | -14.68 Million USD | 39.69% |
| 2015 FY | -13.72 Million USD | 43.64% |
| 2015 Q2 | -4.61 Million USD | 68.54% |
| 2015 Q4 | -13.72 Million USD | 35.6% |
| 2015 Q3 | -21.3 Million USD | -361.31% |
| 2014 FY | -24.34 Million USD | 64.08% |
| 2014 Q3 | -35.06 Million USD | 24.09% |
| 2014 Q4 | -24.34 Million USD | 30.56% |
| 2014 Q2 | -46.19 Million USD | 19.0% |
| 2014 Q1 | -57.02 Million USD | 15.87% |
| 2013 Q1 | -20.08 Million USD | 23.42% |
| 2013 Q4 | -67.78 Million USD | -361.45% |
| 2013 Q3 | -14.69 Million USD | 40.94% |
| 2013 Q2 | -24.87 Million USD | -23.82% |
| 2013 FY | -67.78 Million USD | -158.41% |
| 2012 Q2 | -45.06 Million USD | 16.27% |
| 2012 FY | -26.23 Million USD | -184.88% |
| 2012 Q4 | -26.23 Million USD | 25.39% |
| 2012 Q3 | -35.15 Million USD | 21.99% |
| 2012 Q1 | -53.82 Million USD | -443.87% |
| 2011 FY | -9.2 Million USD | -0.74% |
| 2011 Q4 | -9.89 Million USD | 31.29% |
| 2011 Q3 | -14.4 Million USD | 29.67% |
| 2011 Q2 | -20.48 Million USD | 22.86% |
| 2011 Q1 | -26.55 Million USD | -171.64% |
| 2010 Q1 | -12.07 Million USD | -183.83% |
| 2010 Q4 | -9.77 Million USD | 30.83% |
| 2010 Q2 | -17.96 Million USD | -48.77% |
| 2010 Q3 | -14.13 Million USD | 21.36% |
| 2010 FY | -9.14 Million USD | -114.81% |
| 2009 FY | -4.25 Million USD | 66.27% |
| 2009 Q1 | -6.2 Million USD | 31.65% |
| 2009 Q2 | -13.08 Million USD | -110.79% |
| 2009 Q3 | -5.37 Million USD | 58.92% |
| 2009 Q4 | -4.25 Million USD | 20.85% |
| 2008 Q1 | -4.09 Million USD | 81.13% |
| 2008 Q2 | -17.44 Million USD | -326.3% |
| 2008 FY | -12.61 Million USD | 41.81% |
| 2008 Q3 | -12.56 Million USD | 27.96% |
| 2008 Q4 | -9.08 Million USD | 27.71% |
| 2007 Q4 | -21.68 Million USD | -385.55% |
| 2007 Q1 | -4.78 Million USD | 61.91% |
| 2007 Q2 | -7.98 Million USD | -66.81% |
| 2007 FY | -21.68 Million USD | -72.56% |
| 2007 Q3 | -4.46 Million USD | 44.06% |
| 2006 Q3 | -5.6 Million USD | 56.77% |
| 2006 FY | -12.56 Million USD | 70.17% |
| 2006 Q1 | -19.02 Million USD | 54.84% |
| 2006 Q2 | -12.96 Million USD | 31.85% |
| 2006 Q4 | -12.56 Million USD | -124.2% |
| 2005 Q3 | -30.15 Million USD | -377.03% |
| 2005 Q4 | -42.11 Million USD | -39.68% |
| 2005 Q2 | -6.32 Million USD | 64.74% |
| 2005 Q1 | -17.92 Million USD | 17.31% |
| 2005 FY | -42.11 Million USD | -94.27% |
| 2004 FY | -21.68 Million USD | 23.46% |
| 2004 Q4 | -21.68 Million USD | -49.52% |
| 2004 Q3 | -14.5 Million USD | 33.43% |
| 2004 Q2 | -21.78 Million USD | 2.26% |
| 2004 Q1 | -22.28 Million USD | 21.34% |
| 2003 Q3 | -31.81 Million USD | -3.65% |
| 2003 Q2 | -30.69 Million USD | -387.31% |
| 2003 Q4 | -28.32 Million USD | 10.95% |
| 2003 FY | -28.32 Million USD | -250.03% |
| 2003 Q1 | -6.29 Million USD | 22.18% |
| 2002 Q4 | -8.09 Million USD | -312.49% |
| 2002 FY | -8.09 Million USD | -119.86% |
| 2002 Q2 | -2.84 Million USD | 47.77% |
| 2002 Q1 | -5.44 Million USD | -48.03% |
| 2002 Q3 | -1.96 Million USD | 31.06% |
| 2001 Q2 | -3.73 Million USD | -331.06% |
| 2001 Q1 | -866 Thousand USD | 88.03% |
| 2001 Q3 | -3.1 Million USD | 16.93% |
| 2001 Q4 | -3.68 Million USD | -18.7% |
| 2001 FY | -3.68 Million USD | 49.11% |
| 2000 Q2 | -11.75 Million USD | 50.03% |
| 2000 Q1 | -23.53 Million USD | -572.54% |
| 2000 Q4 | -7.23 Million USD | 23.98% |
| 2000 Q3 | -9.51 Million USD | 19.08% |
| 2000 FY | -7.23 Million USD | -106.72% |
| 1999 FY | -3.49 Million USD | -133.27% |
| 1999 Q1 | -1 Million USD | 33.33% |
| 1999 Q2 | -700 Thousand USD | 30.0% |
| 1999 Q3 | -1.7 Million USD | -142.86% |
| 1999 Q4 | -3.49 Million USD | -105.82% |
| 1998 FY | -1.5 Million USD | 76.19% |
| 1998 Q4 | -1.5 Million USD | 44.44% |
| 1998 Q3 | -2.7 Million USD | 20.59% |
| 1998 Q2 | -3.4 Million USD | 42.37% |
| 1998 Q1 | -5.9 Million USD | 6.35% |
| 1997 Q2 | 700 Thousand USD | 800.0% |
| 1997 FY | -6.3 Million USD | -6200.0% |
| 1997 Q4 | -6.3 Million USD | -1000.0% |
| 1997 Q3 | 700 Thousand USD | 0.0% |
| 1997 Q1 | -100 Thousand USD | 0.0% |
| 1996 Q4 | -100 Thousand USD | 0.0% |
| 1996 Q1 | - USD | -100.0% |
| 1996 Q3 | -100 Thousand USD | 0.0% |
| 1996 FY | -100 Thousand USD | -200.0% |
| 1996 Q2 | - USD | 0.0% |
| 1995 FY | 100 Thousand USD | 0.0% |
| 1995 Q4 | 100 Thousand USD | 0.0% |
| 1995 Q2 | 2.3 Million USD | 43.75% |
| 1995 Q1 | 1.6 Million USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | -1310.00 USD | -189900.0% |
| Arch Therapeutics, Inc. | 5.64 Million USD | 144.066% |
| Evofem Biosciences, Inc. | 42.79 Million USD | 105.816% |
| Nascent Biotech, Inc. | -249.62 Thousand USD | -897.116% |
| Rebus Holdings, Inc. | 305 Thousand USD | 916.066% |
| Santhera Pharmaceuticals Holding AG | -6.3 Million USD | 60.52% |
| Qrons Inc. | 351.42 Thousand USD | 808.255% |
| Adynxx, Inc. | - USD | Infinity% |
| Neon Bloom, Inc. | 622.36 Thousand USD | 499.927% |
| Northwest Biotherapeutics, Inc. | 43.43 Million USD | 105.731% |
| ProtoKinetix, Incorporated | -20.4 Thousand USD | -12096.198% |
| Skye Bioscience, Inc. | -5.72 Million USD | 56.497% |
| Eiger BioPharmaceuticals, Inc. | 15.76 Million USD | 115.79% |
| Nanobac Pharmaceuticals, Incorporated | 4.11 Million USD | 160.442% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | 719.387% |
| SQZ Biotechnologies Company | -36.23 Million USD | 93.132% |
| Intellipharmaceutics International Inc. | 2.24 Million USD | 211.005% |
| Propanc Biopharma, Inc. | 927.18 Thousand USD | 368.447% |
| Mesoblast Limited | 55.85 Million USD | 104.456% |
| Marizyme, Inc. | 18.56 Million USD | 113.404% |
| Genus plc | 190.6 Million USD | 101.306% |
| VioQuest Pharmaceuticals, Inc. | 2.23 Million USD | 211.323% |
| Pharming Group N.V. | 109.8 Million USD | 102.267% |
| Therapeutic Solutions International, Inc. | 860.24 Thousand USD | 389.338% |
| CNBX Pharmaceuticals Inc. | 1.21 Million USD | 305.044% |
| Nymox Pharmaceutical Corporation | 680 Thousand USD | 466.029% |
| ContraFect Corporation | -6.02 Million USD | 58.696% |
| PsyBio Therapeutics Corp. | 134.63 Thousand USD | 1948.647% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.15 Million USD | 315.418% |
| IMV Inc. | 7.67 Million USD | 132.449% |
| AXIM Biotechnologies, Inc. | 5.5 Million USD | 145.239% |
| MultiCell Technologies, Inc. | 90.04 USD | 2764426.966% |
| ONE Bio Corp. | 9.04 Million USD | 127.533% |
| Accustem Sciences Inc. | -733.97 Thousand USD | -239.111% |
| RVL Pharmaceuticals plc | 12.94 Million USD | 119.226% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | 1.36 Million USD | 281.948% |
| Q BioMed Inc. | 4.06 Million USD | 161.305% |
| Emmaus Life Sciences, Inc. | 30.55 Million USD | 108.146% |
| Mosaic ImmunoEngineering Inc. | 1 Million USD | 346.994% |
| Biomind Labs Inc. | 711.4 Thousand USD | 449.873% |
| American Oriental Bioengineering, Inc. | 60.54 Million USD | 104.111% |
| Provectus Biopharmaceuticals, Inc. | 1.99 Million USD | 224.488% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | 12.8 Million USD | 119.435% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | 791.946% |
| THC Farmaceuticals, Inc. | 139.8 Thousand USD | 1880.35% |
| Acro Biomedical Co., Ltd. | 19.86 Thousand USD | 12628.313% |
| Curative Biotechnology, Inc. | 2.2 Million USD | 213.035% |
| GB Sciences, Inc. | 1.74 Million USD | 242.447% |
| Alpha Cognition Inc. | -183.78 Thousand USD | -1254.278% |
| HST Global, Inc. | 96.79 Thousand USD | 2671.467% |
| CSL Limited | 10.52 Billion USD | 100.024% |
| Wesana Health Holdings Inc. | 206.21 Thousand USD | 1306.981% |
| Halberd Corporation | 144.72 Thousand USD | 1819.861% |
| Enzolytics Inc. | 981.65 Thousand USD | 353.551% |
| Agentix Corp. | 37.63 Thousand USD | 6714.228% |
| Resverlogix Corp. | 6.45 Million USD | 138.583% |
| Nuo Therapeutics, Inc. | -673.08 Thousand USD | -269.788% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -2.02 Billion USD | 99.877% |
| Enzon Pharmaceuticals, Inc. | -47.01 Million USD | 94.706% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | 135.2% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | 191.892% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -8.83 Million USD | 71.844% |
| AVAX Technologies, Inc. | -5.9 Million USD | 57.836% |
| Zenith Capital Corp. | 10.06 Thousand USD | 24831.717% |
| Genscript Biotech Corporation | -1.06 Billion USD | 99.765% |
| Ember Therapeutics, Inc. | 200.43 Thousand USD | 1341.818% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | 2.38 Million USD | 204.315% |
| WPD Pharmaceuticals Inc. | 164.5 Thousand USD | 1612.987% |
| Cotinga Pharmaceuticals Inc. | -18.31 Thousand USD | -13487.728% |
| Kadimastem Ltd | -253.1 Thousand USD | -883.398% |
| Helix BioMedix, Inc. | -2.57 Million USD | 3.153% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | 20.27 Million USD | 112.276% |
| BioStem Technologies, Inc. | 4.47 Million USD | 155.657% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | 201.25 Thousand USD | 1336.746% |
| LadRx Corporation | -2.03 Million USD | -22.221% |
| Cell Source, Inc. | 9.23 Million USD | 126.961% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | 491.865% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | 491.865% |
| NovAccess Global Inc. | 2.17 Million USD | 214.255% |
| Affymax, Inc. | -5.59 Million USD | 55.53% |
| Itoco Inc. | 228.3 Thousand USD | 1190.208% |
| Rasna Therapeutics, Inc. | 135.98 Thousand USD | 1930.295% |
| Pathfinder Cell Therapy, Inc. | 4.95 Million USD | 150.212% |
| Mobile Lads Corp. | 484.23 Thousand USD | 614.01% |
| CytoDyn Inc. | 20.26 Million USD | 112.284% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -647.00 USD | -384598.609% |
| NanoSphere Health Sciences Inc. | -9268.34 USD | -26754.863% |
| Alseres Pharmaceuticals, Inc. | 7.7 Million USD | 132.299% |
| SYBLEU INC | 473.71 Thousand USD | 625.423% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 4.45 Million USD | 155.844% |
| International Stem Cell Corporation | 2.59 Million USD | 196.1% |
| Bioxytran, Inc. | 1.89 Million USD | 231.075% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | 4087.951% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | 214.127% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | 3.43 Million USD | 172.481% |
| Adhera Therapeutics, Inc. | 8.55 Million USD | 129.101% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | 772.6 Thousand USD | 422.156% |
| Innovation Pharmaceuticals Inc. | -1.25 Million USD | -99.12% |
| Neutra Corp. | 52.18 Thousand USD | 4869.387% |
| PureTech Health plc | -167.19 Million USD | 98.511% |
| Coeptis Therapeutics, Inc. | -244.9 Thousand USD | -916.3% |
| IXICO plc | -4.44 Million USD | 43.999% |
| IntelGenx Technologies Corp. | 13.21 Million USD | 118.829% |
| Gelesis Holdings, Inc. | 54.85 Million USD | 104.538% |
| CSL Limited | 10.52 Billion USD | 100.024% |
| Cellectis S.A. | -43.81 Million USD | 94.32% |